Proprietary Products in Development
MarkPap® Digital Networking System™ For Telecytopathology:
Future IT Telehealth Center for Telecytopathology
This is the institutialization of our MarkPap® Digital concept in the development of IT Telehealth Center for telecytopathology in Rockville, MD. The Center is an important milestone and a link in our translational research towards robotics and Global Health. This local Center is now in development by a multidisciplinary team of experts at the Shady Grove Innovation Center and the Johns Hopkins University, Montgomery County Campus, Rockville, MD. It is a new enterprise intended to provide high-tech medical diagnostic services 24/7 via web-based network. The prototype of the Local Telehealth Center is built as a modular system that can be further multiplied on State, Country-wide and Global level. The vision is that the Global Center will be responsible for QC/QA, control of other centers for compliance with protocols and polices, change of polices if needs require, customer service for difficult and rare cases, consultations and education. Our new expansion in wireless transmission and mobile health will bring another dimension to the Center, that is expected to be further developed into IT and Wireless Telehealth Center. Telemedicine is a hope to bring efficient and low-cost health care in rural, low-resource areas and the developing world. It is also a hope to decrease disparities in providing health care. The interest is tremendous, and we already signed a Trade Agreement with PR of China. The Center will also bring benefit to the local economy with building a new infrastructure and providing new jobs, new services and revenues and taxes from services.
MarkPap® Wireless is a project in development in the area of Mobile Health - using wireless transmission and cellphone cameras in telemedicine/telecytopathology in areas where the Internet is not available. For more information about our progress in this field, please view Press Releases and Option for m-Health Telecytopathology. This is our current project, and we are concentrated on the development of a Universal Adapter™ that can combine any microscope and any cell cameras for the purpose of telecytopathology. A protoype for the Universal Adapter™ has been accomplished along with feasibility study. Hopkins News, June 2012
Click here to view the abstract on Universal Adapter (FASEB, 2012) and visit our website (42,44,46,47,49).
MarkPap® Test for detection of abnormal cells in oral and anal specimens
Oral cancer is common cancer and constitutes a major health problem in the developing countries. According to the WHO statistics, it represents only 2-4% of the malignancies in the Western countries, but is much more frequent the developing countries, e.g., it accounts for almost 40% of cancers in Indian subcontinent. Although non-invasive and easily accessible for clinical examination and cytological testing, many cases come late, with 5-year survival rate of 50%.
BioSciCon’s MarkPap® biomarker-based platform technology was modified in order to visualize bioactive molecules on oro-pharingeal and anal abnormal specimens. The modification was named APE, with a reagent kit APE-100. Specimen’s are collecting by health providers with a brush, but collection of specimens can be also made with MarkPap® Self Collection Kit and mail to the health providers. The specimen is processed by APE-100 reagent kit. Evaluation can be performed on site if there is a specialist who can read the slides, or MarkPap Telecytopathology service may be offered.
A patent application has been filed with the US Patent and Trademark Office.
Self-sampling for cervical cancer screening, future "home pap" will be made possible because the biomarker is stable in cervico-vaginal fluids, thus amenable for microscopic examination in exfoliated cells. According to the design of this potential device, a woman could obtain a specimen in the privacy of her home using a simple MarkPap Self Kit and bring or mail the sample to the laboratory.
We have been conducting a survey among women on the acceptance of this test (37,40). About 80% of women are enthusiastic about the opportunity. This opportunity would serve women who live in remote parts and do not have access to a medical institution, those who are prohibited to visit gynecologist because of cultural/tradition reason, who can not pay for the test (MarkPap is less expensive), and those who avoid Pap test because they feel uncomfortable or are afraid of pelvic exam. Patent application has been filed with the US Patent and Trademark Office. The same Kit is for self-collection of oral specimens.
MarkPap® Tissue Bank
MarkPap® Solution contains a synthetic antioxidant that improves the preservation of the enzyme activity (biomarker) and the cell integrity. The Solution may be used for conservation of cervical specimens for pharmaceutical industry for the development of molecular-targeting drugs (lysosomal targeting) against invasive cervical cancers. This product is in an initial phase of development.